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Abstract
Background: Interferon-g release assays (IGRAs) for TB have the potential to replace the tuberculin skin test (TST)
in screening for latent tuberculosis infection (LTBI). The higher per-test cost of IGRAs may be compensated for by
lower post-screening costs (medical attention, chest x-rays and chemoprevention), given the higher specificity of
the new tests as compared to that of the conventional TST. We conducted a systematic review of all publications
that have addressed the cost or cost-effectiveness of IGRAs. The objective of this report was to undertake a
structured review and critical appraisal of the methods used for the model-based cost-effectiveness analysis of TB
screening programmes.
Methods: Using Medline and Embase, 75 publications that contained the terms “IGRA”, “tuberculosis” and “cost”
were identified. Of these, 13 were original studies on the costs or cost-effectiveness of IGRAs.
Results: The 13 relevant studies come from five low-to-medium TB-incidence countries. Five studies took only the
costs of screening into consideration, while eight studies analysed the cost-effectiveness of different screening
strategies. Screening was performed in high-risk groups: close contacts, immigrants from high-incidence countries
and healthcare workers. Two studies used the T-SPOT.TB as an IGRA and the other studies used the QuantiFERON-
TB Gold and/or Gold In-Tube test. All 13 studies observed a decrease in costs when the IGRAs were used. Six
studies compared the use of an IGRA as a test to confirm a positive TST (TST/IGRA strategy) to the use of an IGRA-
only strategy. In four of these studies, the two-step strategy and in two the IGRA-only strategy was more cost-
effective. Assumptions about TST specificity and progression risk after a positive test had the greatest influence on
determining which IGRA strategy was more cost-effective.
Conclusion: The available studies on cost-effectiveness provide strong evidence in support of the use of IGRAs in
screening risk groups such as HCWs, immigrants from high-incidence countries and close contacts. So far, only two
studies provide evidence that the IGRA-only screening strategy is more cost-effective.
Background
Screening healthcare workers (HCWs) and close con-
tacts for latent tuberculosis infection (LTBI) and active
tuberculosis (TB) is fundamental to infection control
programmes [1]. For about a century, the tuberculin
skin test (TST) has been used to detect LTBI. However,
the TST has known limitations, including non-specific
reactivity in persons vaccinated with BCG and in those
carrying infection with non-tubercular mycobacteria
(NTM) [2]. Advances in molecular biology have led to
the development of new in-vitro assays that measure the
interferon (INF)-g released by sensitised T cells after sti-
mulation with M. tuberculosis antigens. These tests are
more specific than the TST, because they use antigens
not shared by any of the BCG vaccine strains or by the
more common species of NTM (e.g. M. avium)[ 3 ] .
Besides having higher specificity and sensitivity than the
TST, IGRAs correlate better with surrogate measures of
exposure to M. tuberculosis [4-7] and have a higher pre-
dictive value for LTBI progression to active TB in close
contacts in low-incidence settings [8,9].
There are two different IGRAs available commercially:
the ELISA-based QuantiFERON Gold (QFT-G) or
QuantiFERON Gold In-Tube (QFT-IT) of Cellestis,
Australia, and the T-SPOT-based T-SPOT.TB of Oxford
Immunotech, UK. As experience with the IGRAs evolves
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national recommendations [10-13]. Based purely on
financial considerations, it is usually recommended to
v e r i f yap o s i t i v eT S Tw i t ha nI G R Aa n dt op e r f o r ma
chest x-ray (CXR) on those who test positive with an
IGRA (Nice, DZK and Switzerland).
The first study concerning the cost of introducing the
IGRAs in screening for LTBI was the paper by Mori
and Harada published in 2005 [14]. As this paper was
written in Japanese, only the conclusion is given here: ‘It
was confirmed that the additional use of QFT would
greatly reduce the number of indications for chemopro-
phylaxis cases that have never been infected and that
the use of QFT is cost-effective in spite of its relatively
high unit cost.’ The QFT-G used for analysis was the
second generation of the QuantiFERON-TB. In Europe,
this test has long since been replaced by the Quanti-
FERON-TB Gold In-Tube (QFT-IT). Therefore this
study is of rather historical importance, signalling the
starting point of analysing the cost-effectiveness of
IGRAs in screening for LTBI.
Several cost and cost-effectiveness studies of the intro-
duction of IGRAs in screening for LTBI and treatment
of LTBI based on IGRA results have been published in
recent years. In this systematic review, the available evi-
dence on the costs and cost-effectiveness of TB screen-
ing with IGRAs is analysed.
Methods
Search strategy
On 30 June 2010 with an update on 20 Mai 2011, we
conducted a Medline and Embase search of articles pub-
lished. Search terms included ‘cost + interferon (IGRA)
+ tuberculosis’. The searches were limited to studies
published in German and English. We identified 76
references. Additional studies were identified from the
reference list of articles and relevant reviews. Two of
the authors reviewed all of the abstracts and full texts
using a review form developed for this purpose. The
form contained the following inclusion criteria:
- Study design: cost analysis or cost-effectiveness
studies
- Study population: included high-risk groups (HCWs,
immigrants, close contacts)
- Outcome: costs, incremental cost ratios
- Screening strategies: TST and/or IGRA
- Languages: English (no study written in German was
available)
Definitions
The following definitions of sensitivity, specificity, nega-
tive (NPV) and positive predictive value (PPV) were
included into analysis:
Sensitivity is defined as the proportion of persons with
true latent TB infection proportion who test positive
with the screening test. Specificity is defined as the
number of true negatives in screening for latent TB
infection divided by the sum of true negatives and false
positives. It denotes the ability of a test to assign LTBI-
free as test-negative, irrespective of BCG vaccination
status.
The NPV of a screening test for latent TB infection is
defined as the number of true negative test results
d i v i d e db yt h es u mo ft r u ea n df a l s en e g a t i v er e s u l t s .I f
sensitivity, specificity and prevalence of LTBI are known
in the screened group, the respective formula reads: spe-
cificity × (1-prevalence)/specificity × (1-prevalence) + (1-
sensitivity) × prevalence.
The positive predictive value of the screening test, on
the other hand, is the proportion of test-positive persons
who are truly infected with M. tuberculosis.T h i sc a nb e
found as the ratio of: (sensitivity × prevalence)/sensitivity
× prevalence + (1-specifiicty) × (1-prevalence)
In general, the higher the sensitivity of a screening test
and the lower the LTBI prevalence in the test popula-
tion, the higher the NPV will be. Vice versa, the higher
the specificity of a screening test, and the higher the
LTBI prevalence, the higher the PPV. Of note, in con-
trast to specificity of a test for LTBI which can be mea-
s u r e db yt e s t i n gh e a l t h yp e r s o n sw i t h o u ta n yh i s t o r yo f
exposure to TB and coming from low burden countries,
there is no gold standard against which to establish the
sensitivity of a LTBI screening test. The higher the PPV
o fat e s t ,t h el o w e rt h en u m b e ro fp e r s o n ss c o r e dp o s i -
tive who will need follow-up examination by CXR, and
the lower the number needed to treat in order to pre-
vent a TB case by chemo-prevention and thus the more
cost-effective the implementation of such a test.
Study selection
Studies were included if they used versions of the com-
mercially available IGRAs as a screening test for LTBI
and performed any kind of cost or cost-effectiveness
analysis based on high-risk populations (HCWs, immi-
grants and close contacts). The selected studies are
described in brief. Special emphasis was given to the
assumptions made by the authors about test criteria, the
costs of the TST and the IGRAs as well as the assump-
tions about the probability of progression to active TB
in TST or IGRA positives.
Cost ratios for the TSTs and IGRAs in different coun-
tries were calculated in order to compare the different
costs assumed in the studies without having to take into
account the particular currencies of the countries.
The review was carried out in compliance with the
prisma-statement http://www.prisma-statement.org
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Studies identified
We identified 75 abstracts from the database search.
One abstract was added from references (n = 76). 61
abstracts were excluded because they did not meet the
inclusion criteria. Of these excluded studies, one was
published in Japanese, but provided an English abstract.
Finally, 15 studies were reviewed as full-text articles and
13 articles met the inclusion criteria (Figure 1). One
study did not perform a cost-effectiveness analysis of
INH treatment based on IGRA results and the other
excluded study, which focussed on travellers to high-
incidence countries, used TST only. Of the studies
included, five contained cost analyses while eight con-
tained cost-effectiveness analyses. A short summary of
the strategies used and their basic results are provided
in Tables 1 and 2.
Cost-comparison or cost-optimisation studies
Cost-comparison studies analyse the costs of different
screening strategies but not the effectiveness of the dif-
ferent treatments.
The Swiss paper analysed the cost of introducing the
IGRA in routine screening of contacts and was pub-
lished in 2006 by Wrighton-Smith and Zellweger [15].
For the analysis, probabilities of a positive TST (> = 10
mm) and a positive IGRA (T-SPOT.TB) were taken
from contacts evaluated in 2004 and 2005 in accordance
with the Swiss protocol for contact tracing. Only the
costs of chemoprevention based on the probability of a
positive test were compared while the effect on TB pre-
vention was not taken into consideration. Three strate-
gies were evaluated: IGRA-only, IGRA as a confirmation
test for a positive TST, and TST-only. The two-step
strategy was less expensive than the IGRA-only strategy,
however only by a small margin of 5%. Compared to the
TST-only strategy, the costs of the IGRA-only strategy
were 44% lower. Compared to the strategy using both
tests they were 49% lower.
Fox et al. [16] analysed the costs of screening HCWs
for tuberculosis with the IGRA versus the TST. Based
on Israeli HCWs, the cost analysis comprised 100
HCWs who were referred for routine screening. TST (>
= 10 mm) was positive twice as often as QFT-IT (17%
vs. 34%). Assuming a 50% adherence to chemopreven-
tion, the total cost of screening and treating these 100
HCWs was minimised to € 4,155 by using the QFT-IT
in order to confirm a positive TST (reduction of 49%).
However, the possibility that some HCWs would not
come back to get their TSTs read was not included in
the model. The probability of having an indeterminate
IGRA result was surprisingly high, and the figure pro-
vided by the authors was more than 50% in comparison
to the probability of having a positive QFT result (0.09
vs. 0.17). Under these circumstances the QFT-IT-only
strategy cost 12% less than the TST-only strategy (€
7,248 vs. € 8,217). Observed adherence to chemopreven-
tion in the QFT-positive group was 47%, compared to
12% in the TST-positive group.
Diel et al. [17] used a decision analytic model to simu-
late the costs of screening for LTBI in close contacts
over a two-year time period. They analysed the costs of
the different screening strategies: 1) QFT-only, 2) TST-
only, 3) QFT to confirm a positive TST, and 4) positive
TST followed by a QFT in BCG-vaccinated contacts.
Based on the probabilities of a previous TST/QFT-com-
parison study among close contacts, the combined TST/
QFT strategy was less costly than the TST-only strategy.
The cost of the TST-only strategy was 48.6% higher
than the QFT-only strategy (€ 91.06 vs. € 61.29 per
close contact). The combined screening strategy for all
contacts was the least expensive one (€ 52.02 per con-
tact), followed by the strategy which used QFT to con-
firm a positive TST in contacts with BCG vaccination
and for all others TST-only (€ 55.45)
Hardy et al. [18] analysed the screening cost for LTBI
in 280 immigrants moving from high-incidence coun-
tries to Great Britain based on NICE guidelines or when
using the IGRAs first. With few exceptions (pregnancy,
young age) all immigrants receive chest x-rays (CXRs)
and those from high-incidence countries are also tested
with the TST. If the TST is positive, an IGRA is per-
formed. The alternative protocol provides for QFT-IT in
Medline, Embase
n=75
Added from 
reviews and 
references n=1
Inclusion criteria 
not met n=61
(not published in 
English or German 
n=19)
Total full-text articles 
reviewed
n=15
Inclusion criteria 
not met n=2
Included
n=13
Figure 1 Flow chart of study selection.
Nienhaus et al. BMC Health Services Research 2011, 11:247
http://www.biomedcentral.com/1472-6963/11/247
Page 3 of 10all immigrants and stipulates CXRs in those with a posi-
tive QFT-IT. The number of chest x-rays needed
decreased from 275 to 105 (38%) and the number of
QFT-ITs needed increased from 153 to 280 (183%). The
number of LTBI cases diagnosed increased from 83
using the NICE protocol to 105 (126%) using the QFT-
first protocol. Total costs for the screening of the 280
immigrants were 27% lower for the QFT-first protocol
and costs per detected LTBI case were reduced from £
160.81 to £ 93.16 (-42%). Despite the title ("Cost effec-
tiveness of the NICE guidelines...”) no cost-effectiveness
analysis was performed.
In a further paper, Diel et al. [19] analysed the health
and economic outcomes of isoniazid treatment of 1,000
close contacts followed hypothetically for two years with
respect to isoniazid-related hepatotoxicity and early
post-exposure TB over a two-year period using the
QFT-IT, TST-only or QFT-IT as a test to confirm posi-
tive TST results (TST/QFT-IT). The model incorpo-
rated the results of a prior predictive value study [8]
assuming a higher progression rate to TB disease in
QFT-positive than in TST-positive subjects.
Screening and treatment based on QFT-IT-only (€
215.79 per close contact) was less costly compared to the
TST/QFT-IT strategy (€ 227.89) and the TST-only strat-
egy (€ 232.58) because the more targeted preventive ther-
apy provoked fewer secondary hepatotoxic events. There
were also fewer missed LTBI cases, due to, among other
things, misread or false-negative TST results. This lead
to a lower number of unprevented TB cases.
In summary, the IGRA-only screening strategy was
less costly than the TST screening strategy in two cost
analysis studies [18,19]. Both studies used the QFT-IT.
Three other studies found the two-step strategy to be
less costly [15-17]. The Swiss study analysed the T-
SPOT.TB. In all studies the TST-only strategy was the
most expensive one (Table 1).
Cost-effectiveness studies
Cost-effectiveness studies are done as part of a complete
economic evaluation with the aim of comparing the
costs and consequences of various measures [20]. All
cost-effectiveness studies in this review used Markov
modelling for the transition to different health states.
This dynamic decision analytic technique allows the
progression from LTBI to active TB and the treatment
o u t c o m et ob em o d e l l e do v e rt i m e .T h ef o l l o w - u pp e r -
iod after MTB infection varied from two years to life-
long in the various studies and all studies discounted
t h ec o s t sa n dh e a l t he f f e c t su s i n gar a t eo f3 % .M o s to f
these studies used ‘quality-adjusted life years’ (QALYs)
and ‘life years gained’ (LYGs) as effects and calculated
incremental cost effectiveness ratios (ICERs). One study,
Pooran et al. [21], provided cost per avoided TB cases
instead. A strategy is considered dominant if it is less
expensive and at the same time more effective than the
alternative strategy, which then becomes the dominated
strategy (Table 2).
Pooran et al. [21] analysed the cost-effectiveness of
five different screening scenarios in contact tracing over
a two-year time period in the UK using: 1) TST-only, 2)
the T-SPOT.TB-only, 3) positive TST followed by T-
SPOT.TB, 4) QFT-IT-only, and 5) positive TST followed
by QFT-IT.
Cost-effectiveness was measured as total costs per
active TB case and the ICER per active TB case
Table 1 Summary of five cost analysis studies
Study
period
Country Study
population
Outcome Strategies Results
Wrighton-Smith et al.
[15]
1 year Switzerland 1000 contacts Direct cost TST-only
T-SPOT.TB-only
TST +T-SPOT.TB
€
673,245
€
387,135
€
342,563
Fox et al. [16] Not assessed Israel 100 HCWs Costs for screening and
treatment
TST-only
QFT-only
TST+QFT
€ 8,127
€ 7,280
€ 4,827
Diel et al. [17] 2 years Germany Close contacts Costs TST-only
QFT-only
TST+QFT
TST+QFT in BCG-
vaccinated
€ 91.06
€ 61.29
€ 52.05
€ 55.45
Hardy et al. [18] Not assessed UK Immigrants Total costs/LTBI identified QFT-only
TST+QFT
₤ 93.16
₤ 160.81
Diel et al. [19] 2 years Germany Close contacts Costs TST
QFT
TST+QFT
€ 232.58
€ 215.79
€ 227.89
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Study
period
Country Study population Outcome Strategies Results
Pooran
et al.
[21]
2 years UK Close contacts Incremental
costs/active TB
case prevented
TST-only
T-SPOT.TB-only
TST+T-SPOT
QFT-only
TST+QFT
₤ 47,840
₤ 39,712
₤ 37,206
₤ 42,051
₤ 37,699
Marra et
al. [22]
20 years,
3%
discounted
Canada Close contacts
of foreign-born,
non-aboriginal
Canadian-born and
aboriginal TB cases
Incremental
costs/QALY
QFT (BCG+) + TST
(BCG-)
TST+QFT (BCG+)
+TST (BCG-)
QFT (foreign-born,
aboriginal, BCG+)
+TST (BCG-)
QFT (foreign-born
and aboriginal) +
TST (others)
TST+QFT (foreign-
born, aboriginal,
BCG+) +TST
(others)
TST+QFT (foreign-
born, ab-original) +
TST (others)
TST+QFT (all)
QFT (all)
Dominant
Dominant
CAD 31,930
CAD 40,433
CAD 135,672
Dominated
Dominated
CAD 79,443
Oxlade
et al.
[23]
20 years,
3%
discounted
Canada Close and casual
contacts
Incremental
costs/case
prevented
No screening
TST
QFT
TST+QFT
TST cost saving in close contacts (and casual
contacts from low incidence countries) with
exception of contacts receiving BCG after infancy
(cost savings for QFT)
Immigrants Incremental
costs/case
prevented
No screening
CXR only
TST only
QFT only
TST+QFT
least expensive for subjects from high and
intermediate incidence countries: CAD 875-30,680
Less expensive than QFT: CAD 46,600 (high
incidence) -800,000 (intermediate)
Most expensive: CAD 62, 643 (high incidence) 75,
777 (intermediate)
Least expensive for subjects from low inci-dence
countries): CAD 27,369-45,827
Kowada
et al.[24]
Lifetime,
3%
discounted
Japan Close contacts Incremental
costs/QALY
IGRA-only
TST-only
TST+IGRA
$ 471.54
$ 573.98, dominated by IGRA-only
$ 500.55, dominated by IGRA-only
de Perio
et al.
[25]
Lifetime,
3%
discounted
USA HCWs with
no BCG
vaccination
Incremental
costs/QALY
QFT-IT
QFT-G
TST
Not assessed
$ 14,092
Dominated
HCWs with
BCG vaccination
QFT-IT
QFT-G
TST
Not assessed
$ 103,047
Dominated
Deuffic-
Burban
et al.
[26]
Lifetime,
3%
discounted
France Close contacts Incremental
costs/LYG
No screening
TST ≥ 10 mm +QFT
QFT
TST ≥ 5m m
€ 560
€ 730
Strongly dominated
TST ≥ 5 mm +QFT
TST ≥ 10 mm
Weakly dominated
Strongly dominated
Diel et
al. 2007
[27]
20 years
3%
discounted
Germany Close contacts Incremental
costs/LYG
No treatment
TST > 5
TST > 10
QFT
TST+QFT
$ 30,170
dominant
dominant
dominant
Diel et
al. [28]
20 years,
3%
discounted
Switzerland Close contacts in
middle-aged group
Incremental
costs/LYG
TST > 5 mm
TST > 10 mm
TST > 15 mm
T-SPOT-only
TST+T-SPOT
€ 141,502
€ 107,151
€ 44,831
€ 23,692
€ 23,692
Young group Incremental
costs/LYG
TST > 5 mm
TST > 10 mm
TST > 15 mm
T-SPOT-only
TST+T-SPOT
€ 96,705
€ 70,955
€ 26,451
€ 11,621
€ 11,621
Nienhaus et al. BMC Health Services Research 2011, 11:247
http://www.biomedcentral.com/1472-6963/11/247
Page 5 of 10prevented. Cost for performing the T-SPOT were
assumed to be only ₤ 55. Figures provided for sensitivity
and specificity of the T-SPOT were clearly higher than
those for the QFT (95% and 100% vs. 89% and 95%);
sensitivity for the TST was assumed to be 85%. There
was no stratification with respect to BCG vaccination,
and TST specificity was considered to be 80% for all
contacts. The total cost of TST screening amounted to
₤ 199,598 per 1,000 contacts compared to T-SPOT.TB
at ₤ 203,983, QFT-IT at ₤ 202,921, TST/T-SPOT at ₤
162,387 and TST/QFT-IT at ₤ 157,048. The incremental
cost per active TB case prevented, compared with no
screening, was ₤ 47,840 in TST, ₤ 39.712 in T-SPOT.
TB, ₤ 42,051 in QFT. The most cost-effective strategy
was the two-step strategy with TST and T-SPOT (₤
37,206), followed very closely by the TST/QFT strategy
(₤ 37,699).
To assess the cost-effectiveness of QFT-G vs. the TST
in diagnosing contact persons with active TB cases in
Canada, Marra et al. [22] used a decision analytic Mar-
kov model. Three different screening strategies were
evaluated over a 20-year-period: TST-only, QFT-only
and the two-step strategy using the QFT-G to confirm a
positive TST. The model was stratified by ethnicity (for-
eign-born, non-aboriginal Canadian-born and aborigi-
nal), and BCG vaccination status, as the noted groups
have different rates of prior infection and BCG use.
The most cost-effective strategy was to administer
QFT-G in BCG-vaccinated contacts and reserve TST for
all other patients, assuming specificity for the TST of
more than 99% in all BCG-unvaccinated subgroups, but
of only 96% for the QFT. Driven primarily by the extre-
mely high specificity value, which was not varied in sen-
sitivity analysis, and in combination with an assumed
low BCG vaccination rate, the TST alone-strategy is
dominant (ICER) and an incremental net monetary ben-
efit (INMB) of CA$ 3.70 per contact investigation was
calculated. The least cost-effective strategy was the use
of the QFT-G for all cases, which resulted in an INMB
of CA$ -11.15.
Oxlade et al. [23] used Markov modelling to compare
expected TB cases and costs over 20 years following
screening for TB with different strategies among
hypothetical cohorts of foreign-born immigrants and
close contacts in Canada. Canada. The authors com-
pared five different strategies for immigrants: 1) no
screening, 2) CXR, 3) TST-only, 4) QFT-only, and 5)
QFT for confirmation of a positive TST. For screening
of contact persons they compared three strategies: 1) no
screening, 2) TST only and 3) QFT.
The least costly strategy for immigrants coming from
intermediate and high incidence countries versus non
screening was CXR screening. There, patients were con-
sidered positive for LTBI if they had an “abnormal”
radiograph and subsequently a positive TST. The sensi-
tivity of that method for identifying those infected was
assumed to be 11%. The approach had an incremental
cost of CA$ 825 and $ 30,680 per prevented case when
applied to entry screening of immigrants from high-inci-
dence and intermediate incidence countries, respectively.
In contrast, initial screening with QFT was the most
expensive one when immigrants had no BCG vaccina-
tion or had been BCG vaccinated in infancy.
With respect to contact screening, assuming a TST
specificity of 98% in BCG-unvaccinated cases, of 92%
among infants and 60% among older BCG-vaccinated,
screening of close contacts and casual contacts (when
coming from low-incidence countries) with QFT or TST
would result in savings compared to non-screening. In
such circumstances, TST would generally be more cost-
effective than the QFT with the exception of screening
older close and casual contacts who had received BCG
vaccination. However, Kowada et al. [24] evaluated the
cost-effectiveness of the QFT-IT for TB screening in
close contacts in Japan over the lifetime of a contact
(age 20) in a nearly completely BCG vaccinated society.
They compared the QFT-only strategy with the TST fol-
lowed by the QFT strategy and TST-only strategy. The
target population was a hypothetical cohort of 1,000
immunocompetent 20-year-old close contacts to a spu-
tum smear positive index case. Based on a very low
baseline specificity of the TST among BCG vaccines of
15% and a high prevalence of LTBI, the QFT-only strat-
egy was dominant (US$ 471.54/28.1099 QALYs) com-
pared to the TST/QFT strategy (US$ 500.55/28.1087
QALYs) and the TST-alone strategy (US$ 573.98/
28.1079 QALYs). The incremental cost-effectiveness
ratio of the QFT was a cost saving of US$23.043/
QALYs. Accordingly, the QFT-only strategy is the most
cost-effective for contact investigation in a medium-inci-
dence country like Japan.
In addition, de Perio et al. [25] used a Markov state
transition decision model to compare cost and quality-
adjusted life years (QALYs) with three strategies for a
hypothetical 35-year-old HCW cohort with and without
BCG vaccination, also over a lifetime horizon. Costs and
QALYs were discounted at 3% per year. They compared
two versions of QFT and TST-only and accounted for
inadequate and indeterminate outcomes of both QFTs,
for failure to return for TST reading, and for 2-step
TST testing. In this study, sensitivity of the QFT was
assumed to be clearly higher than that of the TST (76%
vs. 67%) and the drop-out rate for reading of the first
TST was high at 12%. Both IGRAs were more effective
and less costly than the TST. The TST strategy was
thus dominated. The ICER of the QFT-G compared
with the QFT-IT was US$14.092/QALY for BCG-unvac-
cinated and US$103.047/QALY for BCG-vaccinated
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IGRAs leads to superior clinical outcomes and lower
costs than screening with the TST does.
In contrast to these findings, four other cost-effective-
ness studies showed that the two-step strategy with TST
and IGRA was the most cost-effective strategy compared
to the IGRA-only strategy. The first one is a cost-effec-
tiveness study among adult close contacts in France.
Deuffic-Burban [26] generated a decision analytic
model. Lifetime costs and life expectancies for no test-
ing, TST (basically positive at a cut off of ≥ 10 mm) and
QFT-IT only and TST/QFT-IT strategies were calcu-
lated and compared using incremental cost-effectiveness
ratios (ICERs) in euros per life year gained (LYG). The
authors provided a sensitivity figure of only 76% for the
QFT (vs. 73% for the TST) and a very high cost to cost
relation between the QFT (€ 40.50) and the TST (€
2.16). The proportion for adherence to LTBI treatment
as a basic value for their calculations was assumed to be
only 57%, thus reducing the cost for preventative INH
treatment initially started due to false positive TST
results. Given these assumptions, the discounted direct
medical lifetime costs of care per patient were € 417 for
no testing, € 476 for TST, € 443 for QFT and € 435 for
TST/QFT. The TST/QFT strategy was associated with
an ICER of € 560/LYG compared to no testing, while
the QFT-only strategy was associated with an ICER of €
730/LYG. The TST-only strategy, irrespective of
whether a cut off of 5 or 10 mm was used, was strongly
dominated (higher costs and lower life expectancy).
Another study from Diel et al. [27] assessed the cost-
effectiveness of the QFT assay for screening and treat-
ment of close contacts in Germany. They analysed the
health and economic outcomes of isoniazid treatment
for 20-year-old contacts over a 20-year time period
using two different cut-off values for the TST (≥ 5a n d
10 mm), the QFT-only and then QFT as a confirmatory
test for a positive TST. QFT-based treatment led to cost
savings of US$ 542.9 and 3.8 life days per LTBI case
compared to non-treatment, TST-based treatment at 10
mm induration size saved US$ 177.4 and saved 2.0 life
days per test-positive contact. Choosing a 5 mm cut-off
for the TST resulted in additional expenditures and
saved only 0.9 days. Although the ICER for treatment
based on a TST < 5 mm was below the commonly used
willingness-to-pay threshold (US$ 30,170/LYG) it
resulted in unnecessary treatment of 77% due to false-
positive TST results. Combining TST at a 5 mm cut-off
followed by the QFT in a dual-step screening approach
was only marginally less expensive (0.6%) than using the
QFT solely.
In a further study, Diel et al. [28] analysed the out-
comes of INH treatment of close contacts in Switzerland
using the Markov model over a 20-year period following
screening with the TST-only (three different cut-off
v a l u e s :5 ,1 0a n d1 5m m )a n dt h eT - S P O T . T B - o n l yo r
as a two-step strategy with the TST. T-SPOT.TB-based
treatment was cost-effective in both age groups at €
11,621 (20-yr-old cohort) and € 23,692 per LYG (40-yr-
old cohort). Only in the younger group, and with a TST
cut-off of > 15 mm, was the ICER of € 26,451/LY below
the willingness-to-pay threshold of US$ 50,000 (or €
40,195; average exchange rate for 2004: US$ = €
0.8039); all other TST-only options were not cost-effec-
tive. Combination of the TST with T-SPOT.TB slightly
reduced the total cost compared with the T-SPOT.TB
alone, by 4.4% and 5.0% in the younger and older
groups respectively.
The ultimate aim of LTBI screening is the prevention
of progression to active TB via chemopreventative ther-
apy. Whether the introduction of IGRA in the TB
screening of contacts is cost-effective (in terms of pro-
ducing expenditures below a predefined WTP threshold
p e rL Y G )i nt h i sr e s p e c tw a sa nalysed in eight studies
from six different countries (US, Canada, Japan, Switzer-
land, France, UK and Germany). With the exception of
Japan, a country with medium TB prevalence, these
countries are considered to have low TB prevalence. All
studies performed TB screening on groups at high risk
for developing tuberculosis: HCWs [25], close contacts
[15,19,21,22,24,26-28], and immigrants from high-inci-
dence countries [23].
Screening strategies
One study analysed the alternative use of TST or IGRA
[25] and seven studies compared the 1) TST-only, 2)
positive TST followed by IGRA, and 3) IGRA-only stra-
tegies [21-24,26-28].
One study used the T-SPOT.TB [28], one study used
both IGRAs [21] and all the others used a version of the
QFT as IGRA. The QFT-G [22-24,26] was used in four
studies, one study used QFT-G as well as QFT-IT [25]
and three studies used QFT-IT [19,21,27].
Assumptions
a) Specificity and sensibility
Assumptions on TST specificity ranged from as low as
15% in Japanese contacts with repeated BCG vaccination
[24] to 99% in non-vaccinated Canadian contacts [22]
and from 95% up to 100% for the IGRAs [21,25]. Based
on TST-positive/IGRA-negative discordant results in the
source populations, specificity of the TST was assumed
to be 34% in Swiss contacts [28] and 67% in German
contacts [19], regardless of vaccination status (Table 2).
Most studies assumed for TST and IGRA an equal or at
least similar sensitivity for the diagnosis of LTBI (Table
3) ranging from 75-99% for the TST and from 76-100%
for IGRAs. If sensitivity differed between the TST and
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IGRA by a margin of 1-9%.
b) Costs
Because of the different currencies used in the studies,
the costs of the TST and IGRA cannot be compared
directly. Therefore the ratio “cost for IGRA divided by
cost for TST” was calculated (Table 4). This ratio was
highest for the study using the T-SPOT.TB (5.6). For
the QFT studies this ratio ranged from 1.18 to 4.6.
c) Progression rates
Whilst figures for sensitivity and specificity of the TST
and IGRA varied considerably, in all but one study [19]
progression rates to active TB were assumed to be com-
parable for TST and IGRA. Based on literature searches,
progression rates were subdivided depending on dia-
meter in TST in four out of the seven studies
[23,24,27,28]. A fixed lifetime progression rate of 0.01
was used in the US study [25]. In one Canadian study
[23] the progression rate used was available neither
from the text nor from the author (e-mail request). In
the other [22], an age-dependant rate of between 0.0055
(age 20-30) and 0.0018 (age 40-50) per year was used.
Annual risk of progression was assumed to be 0.0037-
0.0056 for the T-SPOT.TB [27] and 0.0030-0.0056 for
the QFT [28]. Based on a recent progression study [8,9]
rates were assumed to be 0.0228 for TST positives and
0.1463 for QFT positives for a two-year period [19]. In
Deuffic-Burban [26], progression rates were calculated
separately following each additional year following
recent infection (8.66% in the first, declining to 0.24%
per year after ≥ 5 years following LTBI). In Pooran et al.
[21], 2.5% for the two years post-exposure was assumed.
Kowada et al. [24] provided a baseline figure of annual
0.37% per Markov cycle.
d) Results of different screening strategies
Regardless of the differences of the assumed progression
rates for active TB and the different costs for the TST
and IGRA, in all studies the TST-only strategy was the
most expensive one. The study of de Perio [21] sup-
ported an IGRA-only strategy vs. the TST first, IGRA-
second strategy, assuming a clearly higher sensitivity of
IGRA than TST given a nearly identical specificity for
t h eQ F T - I T( 1 0 0 % )a n dt h eT S T( 9 8 % ) ,b u td i dn o t
assess a dual-step strategy.
In four out of seven available studies the dual-step
strategy (IGRA following TST positive subjects) was the
least expensive strategy and in two studies [19,24] the
IGRA-only strategy was less expensive. In those two stu-
dies, the most striking difference was found in the Ger-
man analysis that determined the IGRA-only strategy
for contacts to be the most cost-effective, applying dif-
ferent progression rates for TST and IGRA based on
observed progression rates in Germany [8]. In close con-
tacts followed for two years the progression rate in
QFT-IT positives was 6.4 times higher than in close
contacts with TST ≥ 5 mm. Kowada’ss t u d y[ 2 4 ]
assumed an only slightly better sensitivity of the QFT
(76% vs. 71% for the TST) but - as stated above - an
extraordinarily high difference in specificity, which led
to the favourable outcome for the QFT-only strategy.
Clearly, with the exception of de Perio’s work [25], the
difference in outcomes of the compared strategies does
n o tr e s u l tf r o mt h es e n s i t i v ity assumptions made for
TST and IGRA by the various authors. Noteworthy, in
fact, is that lacking or only small differences in the sen-
sitivities assumed [21,24,26,28], now made questionable
by developments in the literature [29], tipped the bal-
ance in favour of the dual-step strategy and against the
IGRA-only strategy.
Table 3 Assumed specificity and sensitivity of TST and
IGRA in cost-effectiveness studies depending on different
countries
Country Specificity Sensitivity
TST/BCG QFT/
(T-SPOT)
No Yes TST QFT/
(T-SPOT)
Canada 2007 [23] 98% 60% 98% 95% 95%
Canada 2008 [22] 99% 62% 96% 99% 99%
Japan 2008 [24] 98% ≥ 15%* 96% 71% 76%
USA 2009 [25] 98% 70% 100% 67% 76%
Germany 2007 [27] 90% 60% 100% 90% 90%
Switzerland 2007 [28] 34% 34% - 88% 95%
UK 2010 [21] - 80% 95% 85% 89% (100%)
France 2010 [26] - 60% 96% 73% 76%
* Depending on repeated BCG in adolescence and adulthood
Table 4 Costs for TST and IGRA depending on different
countries
Country Currency TST IGRA Ratio Difference
Canada 2007 [23] CAD 12.73 19.0 1.49 6.23
Canada 2008 [22] CAD 25.41 45.32 1.78 20.32
Japan 2008 [24] $ 7.4 34.2 4.6 25.8
USA 2009 [25] $ 12.48 31.18 2.5 8.7
Germany 2007 [27]
*
$ 145.99 171.78 1.18 25.79
Germany 2009 [19]
**
€ 117.5 145.98 1.24 27.48
Switzerland 2007
[28]
€ 23 129 5.6 106
UK 2010 [21] ₤ 15.433 55.00/
45.00
3.6/
2.9
39.6/29.6
France 2010 [26] € 10.86 44.83 4.1 33.97
* CXR and consultation if test is positive are included
** Study includes salary of staff
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only strategy were valid in respect of the progression
rates and the specificity of the TST, assumptions about
these two factors appear to be decisive for the outcome
of the cost-effectiveness analysis.
Discussion
Decision-making in healthcare is increasingly based on
cost-effectiveness considerations. This trend is reflected
in most national recommendations concerning TB
screening (e.g. NICE [11], Germany [12], Switzerland
[13]). These recommendations favour a dual-step testing
strategy (TST first, IGRAs second in TST-positive sub-
jects) because in the cost-effectiveness studies available at
the time, the possibility of there being substantially differ-
ent rates of sensitivity and specificity between the meth-
ods being compared was not taken into consideration.
Increased knowledge about progression rates in those
with a positive IGRA helps to improve the outcome mod-
elling of hypothetical cohorts used for cost-effectiveness
analysis. The ultimate aim of LTBI screening is the pre-
vention of progression to active TB via chemoprevention.
Whether the introduction of IGRA in the TB screening
of contacts is cost-effective (in terms of producing expen-
ditures below a predefined WTP threshold per LYG) in
this respect was analysed in eight studies from six differ-
ent countries (US, Canada, Japan, Switzerland, France,
UK and Germany). With the exception of Japan, a coun-
try with medium TB prevalence, these countries are con-
sidered to have low TB prevalence. All studies performed
TB screening on high risk groups for developing tubercu-
losis: HCWs [25], close contacts [15,19,22,24,26-28], or
immigrants from high-incidence countries [23]. However,
given the lack of consistency in the critical assumptions
(e.g. different assumptions on the test parameters, espe-
cially of specificity for both test systems, where assump-
tions varied between 34 and 98% even among non-BCG
vaccinated for the TST and between 95% and 100% for
the IGRAs, it has to be pointed out that the studies con-
sidered in that review cannot be directly compared to
each other. This is also due to the extremely different
cost ratio between TST and IGRA assumed; it varied
between 1.2 and 5.6.
So far, the assumption of a different progression rate
in direct comparison of TST-positive and IGRA-positive
subjects is based on two publications [8,9]. In a latter
abstract, reported at the annual meeting of the BTS in
2009, progression rates for QFT positive contacts were
17.2% in two years; these rates were even higher than
those assumed in the German studies (14.6% and 12.9%,
respectively).
Different assumptions on sensitivity of the TST and
IGRA did not explain why two studies favoured the
IGRA-only strategy, whereas four studies found the
IGRA in TST positives to be the most cost-effective.
However, a recent meta-analysis of TST and IGRA sen-
sitivity for active TB indicates that the sensitivity
assumed for the TST and IGRA was quite high and that
the differences between sensitivity of TST and IGRA
might be as large as 14%, well outside of the 1% to 9%
range assumed in the papers reviewed here [30]. If the
higher sensitivity of the IGRA is confirmed, this would
reduce the costs for the treatment of undetected active
TB and LTBI that progresses to active TB. This would
give further support to the IGRA-only strategy.
With respect to the costs for test performance, differ-
ences occurred not only due to different currencies but
also because some studies used the manufacturer’sc o s t s
needed to perform the tests and other studies also took
the costs for manpower into consideration [19], or com-
bined costs for testing with costs for CXRs, chemopre-
vention [27] and costs for hepatitis developed during
IHN treatment [25].
Comparison of the studies is hampered not only by
the different costs assumed and different assumptions
on test parameters used in the studies but also by differ-
ent strategies in modelling and different outcomes used.
Only three of the eight cost-effectiveness studies used
‘quality-adjusted life years’ (QALYs) as outcome mea-
sures [22,24,25], two [21,23] used averted TB cases and
three used ‘life years gained’ (LYGs) [26-28]. With evol-
ving methodology in cost-effectiveness studies it would
be reasonable to use the same outcomes (QALYs) in
order to increase the comparability of the different
studies.
Most of the studies published so far were performed
in low-to-medium-incidence, high-income countries. It
remains to be analysed whether their findings can be
confirmed in high-incidence countries.
Conclusion
The available studies on cost-effectiveness provide
strong evidence in support of the use of IGRAs in
screening high-risk groups, such as HCWs, immigrants
from high-incidence countries, and close contacts. In
general, the higher unit cost of the IGRAs compared to
that of the TST is compensated for by cost savings
through the more targeted performance of CXRs and
offering of chemoprevention. If the increasing evidence
that IGRA positive subjects have a higher probability of
progression to active TB holds true, the IGRA-only
screening strategy should prove to be the more cost-
effective test. However, until the body of research in this
area is broadened to include generally accepted inputs
for economic analysis, recommendations concerning this
matter should be regarded with caution.
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